Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jordan M. Cloyd

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2373-8433; OpenAlex author ID A5057140415. Sources: ClinicalTrials.gov.

Their work

Papers
63 (first author 8, last author 14)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
139
Papers, trials and grants by year

2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 8 papers · 2021: 8 papers · 2022: 12 papers · 2023: 6 papers · 2024: 7 papers · 2025: 9 papers, 1 trial · 2026: 3 papers

Papers 50 of 63

  1. Fragmented Care for Pancreatic Cancer Patients at a High-Volume Surgical Center. Co-author DOI 10.1016/j.jss.2026.03.035↗
  2. Localized Pancreatic Cancer among Military Beneficiaries: A National Cancer Database Analysis. Co-author DOI 10.1093/milmed/usaf465↗
  3. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  4. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  5. Factors impacting informed decision-making for patients with pancreatic cancer: a qualitative study. Co-author DOI 10.1007/s00520-025-09878-9↗
  6. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Last author DOI 10.1016/j.hpb.2025.08.015↗
  7. Surgical Second Opinion for Pancreatic Cancer Patients. Co-author DOI 10.1097/xcs.0000000000001213↗
  8. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Last author DOI 10.1097/xcs.0000000000001277↗
  9. Recurrence after neoadjuvant therapy for pancreatic cancer: same challenges, new opportunities. First author DOI 10.21037/hbsn-2025-96↗
  10. Neoadjuvant mFOLFIRINOX for resectable pancreatic cancer: increasing evidence, ongoing challenges. First author DOI 10.21037/tgh-24-135↗
  11. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  12. Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Last author DOI 10.3390/cancers17244030↗
  13. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.27558↗
  14. Letter to the editor: Understanding surgical attrition for "resectable" pancreatic cancer. First author DOI 10.1016/j.hpb.2024.01.004↗
  15. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable… First author DOI 10.1093/bjs/znae085↗
  16. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  17. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Last author DOI 10.23736/s2724-5691.23.10150-x↗
  18. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  19. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Co-author DOI 10.6004/jnccn.2023.7099↗
  20. Impact of early vs late palliative care referrals on healthcare utilization in patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-05113-2↗
  21. Evaluating the Quality of Online Information Regarding Neoadjuvant Therapy for Pancreatic Cancer. Last author DOI 10.1007/s12029-022-00879-z↗
  22. Utilization of Palliative and Hospice Care Among Pancreatic Cancer Patients at an Academic Center. Co-author DOI 10.1016/j.jss.2023.03.014↗
  23. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Co-author DOI 10.1245/s10434-023-13230-y↗
  24. Quality of ChatGPT Responses to Questions Related to Pancreatic Cancer and its Surgical Care. First author DOI 10.1245/s10434-023-13777-w↗
  25. Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results. Last author DOI 10.3390/cancers15153967↗
  26. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. Last author DOI 10.1002/jso.26706↗
  27. Rates and Outcomes of Aborted Cancer Surgery among Older Patients with Pancreatic Cancer: a SEER-Medicare Study. Co-author DOI 10.1007/s11605-022-05289-x↗
  28. Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. Co-author DOI 10.1007/s11605-022-05380-3↗
  29. Patterns of health care utilization among Medicare beneficiaries diagnosed with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2021.10.027↗
  30. Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. Last author DOI 10.1016/j.coph.2022.102305↗
  31. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2021.10.010↗
  32. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Co-author DOI 10.1016/j.surg.2021.12.029↗
  33. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.suronc.2022.101849↗
  34. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Last author DOI 10.1093/bjs/znac354↗
  35. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002083↗
  36. Does Extended Lymphadenectomy Help in Pancreatic Cancer? First author DOI 10.1245/s10434-022-11370-1↗
  37. Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study. Last author DOI 10.4251/wjgo.v14.i6.1175↗
  38. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. First author DOI 10.1002/jso.26384↗
  39. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. Co-author DOI 10.1007/s00520-020-05813-2↗
  40. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-021-04984-5↗
  41. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.08.002↗
  42. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic can… Co-author DOI 10.1016/j.radonc.2021.02.035↗
  43. Surgery for pancreatic cancer: recent progress and future directions. First author DOI 10.21037/hbsn-21-18↗
  44. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  45. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. Last author DOI 10.3748/wjg.v27.i27.4383↗
  46. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Co-author DOI 10.1002/cam4.3075↗
  47. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25861↗
  48. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. Co-author DOI 10.1007/s11605-019-04126-y↗
  49. Variations in Healthcare Expenditures Among Medicare Beneficiaries Undergoing Resection of Pancreatic Cancer. Co-author DOI 10.1007/s11605-020-04660-0↗
  50. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. Co-author DOI 10.1016/j.hpb.2020.01.013↗

Trials 1

  1. A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer Principal investigator NCT07124611↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy Michael Pawlik · 33 shared papers, 2019–2026 · strength 5.92
  2. Aslam M. Ejaz · 32 shared papers, 2019–2026 · strength 5.42
  3. Mary E. Dillhoff · 23 shared papers, 2019–2026 · strength 3.72
  4. Zachary J. Brown · 10 shared papers, 2021–2024 · strength 2.53
  5. Allan Tsung · 16 shared papers, 2019–2022 · strength 2.07
  6. Anne M. Noonan · 8 shared papers, 2020–2026 · strength 1.26
  7. Ashish Manne · 6 shared papers, 2024–2026 · strength 1.23
  8. Patrick W. Underwood · 4 shared papers, 2024–2026 · strength 1.21
  9. Patrick L. Quinn · 4 shared papers, 2025–2026 · strength 1.16
  10. Taylor Neilson · 2 shared papers, 2025 · strength 1.07
  11. Shafia Rahman · 5 shared papers, 2023–2026 · strength 1.05
  12. J. Madison Hyer · 7 shared papers, 2019–2025 · strength 1.00
  13. Eric David Miller · 6 shared papers, 2020–2025 · strength 0.98
  14. Heena P. Santry · 6 shared papers, 2020–2022 · strength 0.83
  15. Matthew H. G. Katz · 10 shared papers, 2016–2025 · strength 0.77
  16. Laith I. Abushahin · 5 shared papers, 2020–2026 · strength 0.73
  17. Terence Marques Williams · 6 shared papers, 2020–2025 · strength 0.71
  18. Diamantis I. Tsilimigras · 6 shared papers, 2019–2022 · strength 0.69
  19. Samantha M. Ruff · 3 shared papers, 2022–2024 · strength 0.62
  20. Ahmad B. Hamad · 4 shared papers, 2021–2022 · strength 0.60
  21. Lena Stevens · 3 shared papers, 2022–2024 · strength 0.58
  22. Robert Connor Chick · 2 shared papers, 2023–2026 · strength 0.57
  23. Djhenne M. Dalmacy · 3 shared papers, 2022 · strength 0.55
  24. Somashekar Gopala Krishna · 3 shared papers, 2022–2025 · strength 0.54
  25. Davendra P. S. Sohal · 3 shared papers, 2024–2025 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.